MaxCyte 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay, here we go. We are going to finish out the day at the Stifel 2026 Healthcare Conference on the life sciences side. We are happy to have MaxCyte with us, CEO Maher Masoud, CFO Parmit Ahuja. Gentlemen, thanks very much for spending some time with us today.
Dan, thanks for having us.
Thank you, Dan. I think, Maher, the most logical place to start would be with the acquisition that you made this week, Akron Bio.
Sizeable deal, $150 million. Maybe you can just talk a little bit about that deal, why you did it, and why you think it is an important addition to the company.
Yeah, great question, Dan, and couldn't be more excited about this transaction, this deal, really. Akron is a leading cytokine growth factor ancillary reagent company, a 20-year-old company. They've really built themselves as best-in-class reagents, no different than how MaxCyte is best-in-class electroporation platform, and it really does for us, it strengthens us in the ex vivo market. What Akron has, their reagents are used throughout ex vivo cell therapy, whether it's viral or non-viral. If you look at where they are, they're led by really a great leadership team already. Ezequiel Zylberberg is the Head of Operations there. Dave Smith, industry veteran, is the Head of Commercial there, President and CCO. They've grown this company over the years from 2018 all the way until now at 13% year-over-year growth, consistent growth.
They're spec'd into four commercial therapies right now, one of them from a large pharma where they've had consistent revenue growth, very durable revenue growth. What it does for us, it broadens our breadth of offerings, truly broadens our breadth of offerings. Their reagents are used pre and post-engineering in the non-viral space, that's pre and post our electroporation systems. In the viral space for cell therapy, which is where predominantly most of the reagents are used right now, they've become kind of ubiquitous with reagents used for cell engineering. Really, it broadens us. It now deepens us in the ex vivo non-viral space, increases our TAM, where we're also in the viral space as well, where the majority of cell and gene therapies are. That's mostly ex vivo therapies. This was a competitive process. We've known the Akron team for quite some time.
We know Dave, we know Ezequiel, we know the team there. We're at conferences together oftentimes, many conferences together. This was us and a handful of other bidders in there as well, strategics that were really trying to ensure that we're the ones that end up winning the bid process. Jefferies was on one side, marketing them. The Stifel team here was our exclusive advisor, and it really came to light. When the two teams started talking to each other, it was clear that this is the right fit for MaxCyte. This is the right fit for our future growth. This is now a company where together we have the scale that we really never had before. We're going to be $60 million plus in revenues next year. They bring $28 million of revenue. They're EBITDA positive, $7 million-$8 million EBITDA positive, free cash flow.
This is truly an ideal. It's a hand in glove. We can now become that consolidator of the space where we give best-in-class products to cell therapy developers. Their cytokines and reagents, I can go on and on, truly on and on.
I mean, they out-compete everyone, and I'm sure you have other questions we can get into, but- Well, I mean, maybe along those lines without going too deep into it, I'd love to just sort of get a sense for the differentiation of the portfolio.
I mean, there are other large and small GMP reagent providers Sure out there.
Where do they make their mark with customers?
Yeah, absolutely. What they've done over the years, they've built highly stable, high-quality cytokines and growth factors. They have a closed liquid format, so they have a closed system, liquid bags that can be used straight into the manufacturing process. You don't have to have lyophilized products. All their liquid cytokines, growth factors can be stable at refrigerated temperature. No one has that. High quality, highly spec'd into commercial products. They have four other registrational products that could be approved in the very near term as well that they're spec'd into. So really high quality. They have a drug master file that's also referenced by these developers when they're using their ancillary reagents, similar to MaxCyte's drug master file that's used for our electroporation platform. Just best-in-class products, higher quality, high stability.
Truly, they differentiate themselves by doing what they do best, which is in the reagent market, that's all they do. Similar to how MaxCyte does electroporation, we do it better than anybody else. They cannot compete the big guys.
Yeah. Okay. I mean, a lot of what you come to like about these deals where small companies with good technologies are acquired is just bringing it to a bigger stage with a bigger sales force and getting it out to a broader base. Can you maybe talk a little bit about what you will do with your own commercial organization, what you will do with their commercial organization, and what sales synergies you think might exist in the next one to two years that is sort of tangible things to look for?
Absolutely. Absolutely. That was one of the criteria we're looking for is that we have complementary sales and marketing teams here. This is not a case of one competing with the other one. Most of their presence and most of the revenue is from the U.S. We have a fairly large European commercial team that's sales reps as well as field application scientists that really can begin to build up the revenue for them ex-U.S. We have a fairly robust Asia Pacific team as well, both sales reps and field application scientists that can begin to complement Akron's team here as well. And really, it's our reps in the U.S. and their reps in the U.S. kind of just feeding each other and begin to work with each other.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
